Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q96S66
UPID:
CLCC1_HUMAN
Alternative names:
Mid-1-related chloride channel protein 1
Alternative UPACC:
Q96S66; O94861; Q8WYP8; Q8WYP9; Q9BU25
Background:
Chloride channel CLIC-like protein 1, also known as Mid-1-related chloride channel protein 1, is implicated in chloride ion transport. Its activity is crucial for retina development, highlighting its significance in visual function.
Therapeutic significance:
Linked to Retinitis pigmentosa 32, a degenerative eye disease, this protein's dysfunction underscores its potential as a target for therapeutic intervention. Understanding its role could pave the way for innovative treatments.